dc.contributor | Vall d'Hebron Barcelona Hospital Campus |
dc.contributor.author | Sanegre, Sabina |
dc.contributor.author | Eritja, Núria |
dc.contributor.author | de Andrea, Carlos |
dc.contributor.author | Diaz-Martin, Juan |
dc.contributor.author | Diaz-Lagares, Ángel |
dc.contributor.author | Jácome, María Amalia |
dc.contributor.author | Ramon y Cajal Agüeras, Santiago |
dc.date.accessioned | 2022-03-24T14:03:20Z |
dc.date.available | 2022-03-24T14:03:20Z |
dc.date.issued | 2021-06 |
dc.identifier.citation | Sanegre S, Eritja N, de Andrea C, Diaz-Martin J, Diaz-Lagares Á, Jácome MA, et al. Characterizing the Invasive Tumor Front of Aggressive Uterine Adenocarcinoma and Leiomyosarcoma. Front Cell Dev Biol. 2021 Jun;9:670185. |
dc.identifier.issn | 2296-634X |
dc.identifier.uri | https://hdl.handle.net/11351/7262 |
dc.description | Perfils epigenètics; Matriu extracel·lular; Cèl·lules immunes |
dc.description.sponsorship | This research was supported by grants from the ISCIII and ERDF (PI17/01558 and PI20/01107), by the CIBERONC (contracts CB16/12/00484, CB16/12/0328, CB16/12/00363, CB16/12/00364, CB16/12/00481, and CB16/12/00231) and Grupos Coordinados Estables from the Asociación Española Contra el Cáncer (AECC). ÁD-L was funded by a contract “Juan Rodés” from the ISCIII (JR17/00016). The funders had no involvement in the research process nor in the preparation and submission of the article. |
dc.language.iso | eng |
dc.publisher | Frontiers Media |
dc.relation.ispartofseries | Frontiers in Cell and Developmental Biology;9 |
dc.rights | Attribution 4.0 International |
dc.rights.uri | http://creativecommons.org/licenses/by/4.0/ |
dc.source | Scientia |
dc.subject | Úter - Tumors |
dc.subject | Músculs - Càncer |
dc.subject | Marcadors tumorals |
dc.subject.mesh | Leiomyosarcoma |
dc.subject.mesh | Uterine Neoplasms |
dc.subject.mesh | Biomarkers, Tumor |
dc.title | Characterizing the Invasive Tumor Front of Aggressive Uterine Adenocarcinoma and Leiomyosarcoma |
dc.type | info:eu-repo/semantics/article |
dc.identifier.doi | 10.3389/fcell.2021.670185 |
dc.subject.decs | leiomiosarcoma |
dc.subject.decs | neoplasias uterinas |
dc.subject.decs | marcadores tumorales |
dc.relation.publishversion | https://doi.org/10.3389/fcell.2021.670185 |
dc.type.version | info:eu-repo/semantics/publishedVersion |
dc.audience | Professionals |
dc.contributor.organismes | Institut Català de la Salut |
dc.contributor.authoraffiliation | [Sanegre S] Cancer CIBER (CIBERONC), Madrid, Spain. Department of Pathology, School of Medical, University of Valencia-INCLIVA, Valencia, Spain. [Eritja N] Cancer CIBER (CIBERONC), Madrid, Spain. Institut de Recerca Biomèdica de LLeida (IRBLLEIDA), Institut d’Investigació Biomèdica de Bellvitge (IDIBELL), Department of Pathology, Hospital U Arnau de Vilanova and Hospital U de Bellvitge, University of Lleida - University of Barcelona, Barcelona, Spain. [de Andrea C] Cancer CIBER (CIBERONC), Madrid, Spain. Clínica Universidad de Navarra, University of Navarra, Pamplona, Spain. [Diaz-Martin J] Cancer CIBER (CIBERONC), Madrid, Spain. Institute of Biomedicine of Sevilla, Virgen del Rocio University Hospital/CSIC/University of Sevilla/CIBERONC, Seville, Spain. [Diaz-Lagares Á] Cancer CIBER (CIBERONC), Madrid, Spain. Cancer Epigenomics, Translational Medical Oncology Group (Oncomet), Health Research Institute of Santiago (IDIS), University Clinical Hospital of Santiago (CHUS/SERGAS), Santiago de Compostela, Spain. [Jácome MA] Department of Mathematics, MODES Group, CITIC, Faculty of Science, Universidade da Coruña, A Coruña, Spain. [Ramon Y Cajal S] Cancer CIBER (CIBERONC), Madrid, Spain. Servei de Patologia, Vall d’Hebron Hospital Universitari, Barcelona, Spain. Universitat Autònoma de Barcelona, Bellaterra, Spain |
dc.identifier.pmid | 34150764 |
dc.identifier.wos | 000662202000001 |
dc.rights.accessrights | info:eu-repo/semantics/openAccess |